Drug intelligence / Profile preview

RCN301

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

RCN301 is an injectable drug developed for use in patients requiring central parenteral nutrition, particularly in postoperative settings. It is being evaluated as a treatment option to provide nutritional support intravenously when oral or enteral feeding is not possible or adequate. The drug has been studied in randomized, open-label phase 3 clinical trials comparing its safety and efficacy to other parenteral nutrition formulations in postoperative patients.

Beyond the preview

Go deeper on RCN301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCN301.

Explore the full profile